Compare Quest Diagnostics Inc (DGX) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Unity Software Inc — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Unity Software Inc trades at $46.1 (market cap $20.00B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.52% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Unity Software Inc for 50 Days on average.
| DGX | U | |
|---|---|---|
Market Cap | $25.06B | $20.00B |
Volume | 927,361 | 12,798,386 |
Sector | Health | Technology |
52-Week High | $247.45 | $49.47 |
52-Week Low | $173.49 | $17.13 |
Typical Hold Time | 56 Days | 50 Days |
Enterprise Value | $30.82B | $19.88B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Unity Software (U) trades at $45.89, up 2.09% today, with strong technical momentum and bullish analyst sentiment. The stock shows improving fundamentals with revenue stabilizing around $1.8B-$2.0B and narrowing losses, though profitability remains negative. Recent catalysts include Meta VR Glasses support and positive sector momentum from Accenture's earnings. Technical indicators show the stock trading near resistance at $46 with overbought short-term RSI conditions.
Outlook remains cautiously optimistic with 82% analyst buy ratings and $45.27 consensus target. Key opportunities include VR/AR growth and advertising platform expansion, while risks center on persistent losses, high valuation multiples, and competitive pressures. The stock's current level near analyst targets suggests limited near-term upside without significant earnings improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
